Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Barrett Esophagus 1

Interventions

fludarabine 6trametinib 5Specimen Handling 5Standard of Care 4Practice Guidelines as Topic 4Magnetic Resonance Spectroscopy 4fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3Melphalan 3Interviews as Topic 3GSK2636771 3Cyclophosphamide 3Crizotinib 3Busulfan 3Biopsy 3Antilymphocyte Serum 3AP 1903 reagent 3venetoclax 2thymoglobulin 2palbociclib 2osimertinib 2letermovir 2dabrafenib 2capivasertib 2binimetinib 2adavosertib 2X-Rays 2Thiotepa 2Tacrolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hematologic Neoplasms × Itraconazole × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡